294 related articles for article (PubMed ID: 7857117)
1. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Snow JL; Gibson LE
Arch Dermatol; 1995 Feb; 131(2):193-7. PubMed ID: 7857117
[TBL] [Abstract][Full Text] [Related]
2. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
[TBL] [Abstract][Full Text] [Related]
3. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
Firooz A; Ghandi N; Hallaji Z; Chams-Davatchi C; Valikhani M; Karbakhsh Davari M
Arch Dermatol; 2008 Sep; 144(9):1143-7. PubMed ID: 18794458
[TBL] [Abstract][Full Text] [Related]
4. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
7. An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions.
Vestergaard T; Bygum A
Clin Exp Dermatol; 2010 Mar; 35(2):140-4. PubMed ID: 19663853
[TBL] [Abstract][Full Text] [Related]
8. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.
Tavadia SM; Mydlarski PR; Reis MD; Mittmann N; Pinkerton PH; Shear N; Sauder DN
J Am Acad Dermatol; 2000 Apr; 42(4):628-32. PubMed ID: 10727309
[TBL] [Abstract][Full Text] [Related]
9. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.
Szumlanski CL; Honchel R; Scott MC; Weinshilboum RM
Pharmacogenetics; 1992 Aug; 2(4):148-59. PubMed ID: 1306116
[TBL] [Abstract][Full Text] [Related]
10. [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].
Zhan ZP; Liang LQ; Yang XY; Wang YX; Huang M; Li H
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1734-7. PubMed ID: 17919375
[TBL] [Abstract][Full Text] [Related]
11. The role of genetic variation in thiopurine methyltransferase activity and efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Anstey A; Lennard L
Arch Dermatol; 1995 Sep; 131(9):1087-8. PubMed ID: 7661617
[No Abstract] [Full Text] [Related]
12. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
14. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.
Song DK; Zhao J; Zhang LR
J Clin Pharm Ther; 2006 Dec; 31(6):627-35. PubMed ID: 17176368
[TBL] [Abstract][Full Text] [Related]
15. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype.
Arenas M; Duley JA; Ansari A; Shobowale-Bakre EA; Fairbanks L; Soon SY; Sanderson J; Marinaki AM
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1403-5. PubMed ID: 15571267
[TBL] [Abstract][Full Text] [Related]
16. Segregation analysis of human red blood cell thiopurine methyltransferase activity.
Vuchetich JP; Weinshilboum RM; Price RA
Genet Epidemiol; 1995; 12(1):1-11. PubMed ID: 7713396
[TBL] [Abstract][Full Text] [Related]
17. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
18. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.
Corominas H; Domènech M; González D; Diaz C; Roca M; García-González MA; Peña S; Baiget M
Am J Gastroenterol; 2000 Sep; 95(9):2313-7. PubMed ID: 11007234
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.
Larussa T; Suraci E; Lentini M; Nazionale I; Gallo L; Abenavoli L; Imeneo M; Costanzo FS; Cuda G; Luzza F
Eur J Intern Med; 2012 Apr; 23(3):273-7. PubMed ID: 22385887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
